Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs.
Gulsen OzenSofia PedroBryant R EnglandBella MehtaFrederick WolfeKaleb D MichaudPublished in: ACR open rheumatology (2019)
TNFis and non-TNFi bDMARDs were associated with an increased SI risk compared with csDMARDs in RA, even after accounting for risk-associated patient characteristics.